Phase II Randomized Controlled Trial to Evaluate the Clinical and Histological Effects of Oral Isotretinoin for the Treatment of Photoaging on Face and Forearms
Overview
- Phase
- Phase 2
- Intervention
- oral isotretinoin and Mexoryl SX / XL
- Conditions
- Photoaging
- Sponsor
- Federal University of São Paulo
- Enrollment
- 32
- Locations
- 1
- Primary Endpoint
- histological findings
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
A clinical and histological randomized controlled phase II trial to evaluate the efficacy and safety of oral isotretinoin for treating photoaging was performed with 32 menopausal or sterilized women aged 40-55y. The subjects were included in two randomly selected groups: A- 21 women received 20mg oral isotretinoin 3x week, moisturizer, sunscreen SPF 60 during three months; B- 11 women received only same moisturizer/sunscreen.
Detailed Description
Clinical assessment ranging from -2=very bad to +2=very good for all patients. Also, profilometry, corneometer and skin elasticity tests in periocular regions and left forearm; skin biopsy on left forearm before/after treatment in B and in 10 randomly selected patients from A. Microscopic evaluation of corneal layer and epidermal thickness, dermal elastosis, new collagen and p53 epidermal expression performed by quantitative digital image analysis. Blind evaluations (group/time) conducted by two independent observers. Clinical evaluation results showed no alterations (0) or slight improvement (+1) for all patients; profilometry, corneometer and skin elasticity measurements presented a significant difference in pre and post treatment values (p=0,001 to 0,028) with no differences between A/B. Regarding histological findings and p53 expression no previous differences between groups before the treatment were observed (p\>0,1).Quantitative microscopic digital analysis demonstrated no differences between groups at the end of the study for the majority of variables. However, slight but significant difference between A/B subjects was found for p53 with major expression reduction for those treated with oral isotretinoin \[0,66±0,31 vs 0,94±0,34 respectively (p=0,04)\]. The main side effects were cheilitis in 15 patients (75%) and xerophthalmia in 5 (25%). No significant alterations occurred in biochemical tests.
Investigators
Edileia Bagatin
Edileia Bagatin
Federal University of São Paulo
Eligibility Criteria
Inclusion Criteria
- •menopausal or sterilized women
Exclusion Criteria
- •woman at risk of pregnancy, with alterations on liver function or lipid profile
Arms & Interventions
A
A - 21 subjects were treated 20mg isotretinoin 3/week plus moisturizer and sunscreen,for three months; 10 randomly selected were submitted to skin biopsies before and after the end of treatment
Intervention: oral isotretinoin and Mexoryl SX / XL
B
11 subjects received only the same moisturizer/sunscreen
Intervention: Mexoryl XL / SX
Outcomes
Primary Outcomes
histological findings
Time Frame: before and after 3 months
Secondary Outcomes
- laboratory tests(before, after 1 and 3 months)